The price of multiple sclerosis drugs is astronomical and rapidly rising. But some drugs are now off-patent, and generic or biosimilar formulations offer new, cheaper alternatives. But are they just as good? This video takes a look at drugs such as glatiramer acetate (copaxone/glatopa), tecfidera, gilenya, aubagio, and tysabri and their alternative formulations.
Is it better to take a “stronger” disease modifying therapy such as Tysabri or a “weaker” and more conservative disease modifying therapy? Many people who have low baseline disability prefer a cautious approach, but this study shows that the “stronger” drugs are actually better if taken by less disabled people early on
The article I am discussing: https://www.mdpi.com/1424-8247/14/2/8…